Hot Pursuit     25-Jul-23
AstraZeneca hits 52-week high on DCGI nod for Dapagliflozin tablets
AstraZeneca Pharma India rose 1.58% to Rs 3,828.90 after the Drugs Controller General of India granted permission to import pharmaceutical formulations of a new drug for sale in Form CT-20, which is a marketing authorisation for Dapagliflozin tablet.
Dapagliflozin tablets are indicated for the treatment of heart failure in adults.

The receipt of this permission paves way for the launch of Dapagliflozin Tablets in India for the specified indication, subject to the receipt of related statutory approvals and licenses, said the drug maker.

Astrazeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company.

The company's standalone net profit declined 38.3% to Rs 17.27 crore in Q4 FY23 as compared with Rs 27.98 crore in Q4 FY22. Net sales jumped 22.7% year on year to Rs 284.70 crore in Q4 FY23.

The scrip hit a 52-week high at Rs 3,882.70 in intraday today on the BSE.

Previous News
  Astrazeneca Pharma India standalone net profit rises 167.30% in the June 2023 quarter
 ( Results - Announcements 14-Aug-23   14:37 )
  Nifty above 22,950; European mkt opens lower
 ( Market Commentary - Mid-Session 28-May-24   13:43 )
  Astrazeneca Pharma India fixes record date for interim dividend
 ( Market Beat - Reports 10-Aug-21   10:00 )
  Board of Astrazeneca Pharma India recommends Final Dividend
 ( Corporate News - 28-May-22   10:09 )
  Volumes spurt at Elgi Equipments Ltd counter
 ( Hot Pursuit - 05-Jul-22   14:30 )
  Volumes spurt at Astrazeneca Pharma India Ltd counter
 ( Hot Pursuit - 26-Nov-21   11:00 )
  Astrazeneca Pharma India standalone net profit declines 2.44% in the March 2020 quarter
 ( Results - Announcements 18-May-20   18:30 )
  Astrazeneca Pharma India standalone net profit rises 172.47% in the September 2022 quarter
 ( Results - Announcements 11-Nov-22   17:08 )
  AstraZeneca Pharma India appoints director
 ( Corporate News - 13-Aug-20   10:21 )
  Castrol India Ltd leads gainers in 'A' group
 ( Hot Pursuit - 22-Dec-23   12:00 )
  Astrazeneca Pharma India standalone net profit declines 54.63% in the September 2021 quarter
 ( Results - Announcements 10-Nov-21   08:11 )
Other Stories
  RVNL gains on emerging as L-1 bidder for Rs 133-cr railway project
  03-Jul-24   15:38
  Cholamandalam Financial Holdings Ltd leads losers in 'A' group
  03-Jul-24   15:00
  Sakuma Exports Ltd leads losers in 'B' group
  03-Jul-24   14:45
  NTPC power generation climbs 9.5% YoY in Q1
  03-Jul-24   14:41
  Volumes soar at MMTC Ltd counter
  03-Jul-24   14:30
  Oil and Gas shares fall
  03-Jul-24   14:00
  Real Estate stocks edge lower
  03-Jul-24   14:00
  Energy stocks edge lower
  03-Jul-24   14:00
  Sundaram-Clayton gains after board OKs to raise funds upto Rs 400 cr
  03-Jul-24   13:38
  JSW Infra's subsidiary concession agreement V.O. Chidambaranar Port Authority
  03-Jul-24   13:34
Back Top